Latest news for Leveljump Healthcare (OTC:JMPHF) Stock

Leveljump Healthcare Corp is engaged in the business of providing radiology solutions for hospitals, emergency rooms, and private clinics. The company offers telehealth services that are designed to provide a doctor-to-doctor collaboration and diagnosis allowing effective patient care.

News

Penny Stocks

Health Care

Offerings

General

JMPHF

TSXV:JUMP

Leveljump Plans To Raise C$2M Via Equity Offering

LEVELJUMP HEALTHCARE CP by Leveljump Healthcare Corp.

Leveljump Healthcare Corp

CMCSA

DataBee, From Comcast Technology, Launches A Gen AI Powered Chatbot To Tackle The Challenge Of Finding And Validating Asset Owners

Guidance

SOFI

SoFi Sees FY24 Revenue $2.425B-$4.465B Vs $2.783B Estimate, $2.39B-$2.43B Prior

B of A Securities analyst Derik De Bruin maintains Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>) with a Neutral and raises the price target from $118 to $127.

Price Target

Analyst Ratings

RVTY

B of A Securities Maintains Neutral on Revvity, Raises Price Target to $127

Laboratory Corporation Of America Holdings

Labcorp Expands Partnership With Ultima Genomics To Boost Whole Genome Sequencing Applications And Oncology Testing Capabilities

2024 Financial Guidance
Incyte is raising the low end of its full year 2024 Jakafi revenue guidance as well as updating its full year 2024 research and development guidance to reflect the ongoing impact of the acquisition of Escient Pharmaceuticals. The research and development guidance excludes $691 million of upfront consideration recorded relating to the acquisition of Escient Pharmaceuticals. Incyte is maintaining its full year 2024 other hematology/oncology revenue guidance, as well as its cost of product revenue and selling, general and administrative guidance. Incyte&#39;s guidance is summarized below. Guidance does not include revenue from any potential new product launches or the impact of any potential future strategic transactions.
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
Current
</td>
<td colspan="1" rowspan="1">
Previous
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Jakafi net product revenues
</td>
<td colspan="1" rowspan="1">
$2,710 - $2,750 million
</td>
<td colspan="1" rowspan="1">
$2,690 - $2,750 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Other Hematology/Oncology net product revenues(1)
</td>
<td colspan="1" rowspan="1">
Unchanged
</td>
<td colspan="1" rowspan="1">
$325 - $360 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
GAAP Cost of product revenues
</td>
<td colspan="1" rowspan="1">
Unchanged
</td>
<td colspan="1" rowspan="1">
7 &ndash; 8% of net product revenues
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP Cost of product revenues(2)
</td>
<td colspan="1" rowspan="1">
Unchanged
</td>
<td colspan="1" rowspan="1">
6 &ndash; 7% of net product revenues
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
GAAP Research and development expenses
</td>
<td colspan="1" rowspan="1">
$1,755 - $1,800 million
</td>
<td colspan="1" rowspan="1">
$1,720 - $1,760 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP Research and development expenses(3)
</td>
<td colspan="1" rowspan="1">
$1,615 - $1,655 million
</td>
<td colspan="1" rowspan="1">
$1,580 - $1,615 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
GAAP Selling, general and administrative expenses
</td>
<td colspan="1" rowspan="1">
Unchanged
</td>
<td colspan="1" rowspan="1">
$1,210 - $1,240 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP Selling, general and administrative expenses(3)
</td>
<td colspan="1" rowspan="1">
Unchanged
</td>
<td colspan="1" rowspan="1">
$1,115 - $1,140 million
</td>
</tr>
</tbody>
</table>

Biotech

Earnings

INCY

Incyte Forecasts 2024 Jakafi Net Product Revenue Of $2.71B-$2.75B Versus Prior Guidance Of $2.69B-$2.75B

This product family is intended to provide a pathway through which medical instruments, such as balloon dilatation catheters, guidewires, or other therapeutic devices, may be introduced into the peripheral vasculature or chambers and coronary vasculature of the heart.

BCDA

BioCardia Says Submitted 510(K) For Approval Of Its Patented Morph DNA Steerable Introducer Sheath

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) with a Buy and maintains $10 price target.

Reiteration

EKSO

HC Wainwright & Co. Reiterates Buy on Ekso Bionics Holdings, Maintains $10 Price Target

NEOG

Neogen Expects FY2025 Adjusted EBITDA Of $215M-$235M, While Capital Expenditures Are Expected To Be Approximately $85M, Including Approximately $55M Related Specifically To The Integration Of The Former 3M Food Safety Division

Howmet Aerospace Sees Q3 Revenue $1.845B-$1.865B vs $1.81B Est., Adj. EPS $0.63-$0.65 vs $0.60 Est.; Sees FY24 Revenue $7.40B-$7.48B vs $7.33B Est., Adj. EPS $2.53-$2.57 vs $2.39 Est.

LGI Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) reported quarterly earnings of $2.48 per share which beat the analyst consensus estimate of $2.22 by 11.71 percent. The company reported quarterly sales of $602.497 million which missed the analyst consensus estimate of $625.200 million by 3.63 percent. This is a 6.63 percent decrease over sales of $645.270 million the same period last year.

Earnings Beats

Earnings Misses

LGIH

LGI Homes Q2 2024 GAAP EPS $2.48 Beats $2.22 Estimate, Sales $602.497M Miss $625.200M Estimate

B of A Securities analyst Wamsi Mohan maintains Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with a Neutral and lowers the price target from $44 to $41.

B of A Securities Maintains Neutral on Sensata Technologies, Lowers Price Target to $41

Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) (&quot;TRNR&quot; or &quot;the Company&quot;), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced that it has secured exclusive distribution and a six-figure initial order for CLMBR in Germany, the largest fitness market outside the United States.
<ul>
<li>
German Distributor placed six-figure initial order that is expected to ship in the third quarter of 2024
</li>
<li>
Germany is the largest fitness market after the United States
</li>
<li>
Germany&#39;s largest fitness company, RSG Group, owns Gold&#39;s Gym and McFIT among other brands
</li>
</ul>

TRNR

Interactive Strength Announced Exclusive Distribution for CLMBR in Germany and Receives Six-Figure Initial Order

Getty Realty Prices 3.5M Shares At A Public Offering Price Of $30.10 Per Share

SoFi Sees Q3 2024 Adj. Net Revenue $625M-$645M Vs $610.9M Estimate

Neogen Initiates Its Full-year Outlook For Fiscal Year 2025, With Revenue Guidance Of $925M-$955M Versus Consensus Of $938.743M

Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.20 by 5 percent. This is a 10.53 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $284.39 million which missed the analyst consensus estimate of $289.06 million by 1.61 percent. This is a 0.30 percent increase over sales of $283.54 million the same period last year.

HAYW

Hayward Holdings Q2 Adj $0.21 Beats $0.20 Estimate, Sales $284.39M Miss $289.06M Estimate

Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) reported quarterly earnings of $2.31 per share which beat the analyst consensus estimate of $1.98 by 16.67 percent. This is a 40.31 percent decrease over earnings of $3.87 per share from the same period last year. The company reported quarterly sales of $38.911 billion which beat the analyst consensus estimate of $35.426 billion by 9.84 percent. This is a 8.87 percent increase over sales of $35.740 billion the same period last year.

Phillips 66 Q2 2024 Adj. EPS $2.31 Beats $1.98 Estimate, Sales $38.911B Beat $35.426B Estimate

HC Wainwright &amp; Co. analyst Arthur He initiates coverage on Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Buy rating and announces Price Target of $4.

Initiation

ADAP

HC Wainwright & Co. Initiates Coverage On Adaptimmune Therapeutics with Buy Rating, Announces Price Target of $4

He will join the Board on 16 September 2024 and will succeed Roberto Quarta as Non-Executive Chair of WPP from 1 January 2025.

Management

WPP Appoints Philip Jansen To Its Board As Non-Executive Director And Chair-Designate

EARNINGS&nbsp;GUIDANCE&nbsp;
AEP management reaffirms its 2024 operating earnings&nbsp;guidance&nbsp;range of&nbsp;$5.53&nbsp;to&nbsp;$5.73&nbsp;per share. Operating earnings could differ from GAAP earnings for matters such as impairments, divestitures or changes in accounting principles. AEP management is not able to forecast if any of these items will occur or any amounts that may be reported for future periods. Therefore, AEP is not able to provide a corresponding GAAP equivalent for 2024 earnings&nbsp;guidance.
Reflecting special items recorded through the&nbsp;second quarter, the estimated earnings per share on a GAAP basis would be&nbsp;$5.56&nbsp;to&nbsp;$5.76&nbsp;per share. See the table below for a full reconciliation of 2024 earnings&nbsp;guidance

AEP Reaffirms Its 2024 Outlook: Sees Operating EPS Of $5.53-$5.73 Vs. $5.62 Consensus; Long-Term Growth Rate Of 6%-7%

Leveljump Healthcare reports Q2 results

LevelJump Healthcare acquires four Alberta-based diagnostic imaging clinics

LevelJump Healthcare applies to update its preferred share unit offering

Leveljump Healthcare reports Q3 results

Press Releases

The Watchlist by The Market Herald Releases New Interviews with Leveljump Healthcare, Kootenay Silver, Sendero Resources, Nextech3D.ai, and Canada Nickel Company Discussing their Latest News

CNIKF

CSE:NTAR

NEXCF

TSX:SEND

TSXV:CNC

TSXV:KTN

Leveljump Healthcare

<ul>
	<li>Leveljump Healthcare Corp&nbsp;(TSXV:<a class="ticker" href="https://www.benzinga.com/stock/JUMP#TSXV">JUMP</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/JMPHF#OTC">JMPHF</a>) announced a&nbsp;<a class="editor-rtfLink" href="https://finance.yahoo.com/news/leveljump-announces-2-million-non-171400966.html" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">non-brokered private placement financing</a>&nbsp;of up to 13.33 million units at C$0.15 per unit for gross proceeds of up to C$2 million.</li>
	<li>Each unit will consist of one common share of Leveljump and one common share purchase warrant.</li>
	<li>Each Warrant will entitle the holder to acquire one additional common share of Leveljump at an exercise price of C$0.20 with an expiry date of March 31, 2024.</li>
	<li>The net proceeds from the financing will be used towards acquisitions and for general working capital purposes.</li>
	<li>Price Action: JUMP shares are trading at C$0.15 on TSXV on the last check Wednesday.</li>
</ul>

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Leveljump Healthcare

News

Latest news for Leveljump Healthcare (OTC:JMPHF) Stock

Wednesday, April 06, 2022